TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6224469
Drug: Thiabendazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiabendazole (50 mg kg‐1 daily for two days)
Study: 6224469
Drug: Thiabendazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiabendazole (100 mg kg‐1 daily for two days)
Study: 6224469
Drug: Metronidazole (30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (30-40 mg kg‐1 t.d.s. for three days)
Study: 21999719
Drug: Community care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community care (CC) participants received smoking-cessation pamphlets and information on local treatment programs
Study: 19843797
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 7 mg
Study: 19843797
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 8 mg
Study: 17204951
Drug: Omeprazole (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (0.7 mg/kg/d)
Study: 11228177
Drug: Intravenous doxercalciferol
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous doxercalciferol (1alphaD(2))
Study: 11228177
Drug: Oral doxercalciferol
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doxercalciferol (1alphaD(2))
Study: 9442826
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline nasal spray (placebo)
Study: 7931476
Drug: Observation subsequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation subsequent to local treatment
Study: 3495653
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 1.8 g protein/100 kcal with whey/casein ratios 18:82, 34:66, or 50:50
Study: 27107209
Drug: 8IU low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8IU low dose intranasal oxytocin
Study: 20496733
Drug: Sulfasalazine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (oral administration)
Study: 18005471
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.25 microg kg(‐1) min(‐1))
Study: 18005471
Drug: Fentanyl (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (total dose 2.6 +/- 0.3 mg)
Study: 15956292
Drug: Vitamin D2-fortified
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2-fortified cheese (5880 IU/56.7-g serving)
Study: 15956292
Drug: Water (32,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (32,750 IU/250 mL)
Study: 12109926
Drug: Antipsychotics (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (specific agents not detailed)
Study: 12109926
Drug: QTc-prolonging drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: QTc-prolonging drugs
Study: 12109926
Drug: Antipsychotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics with marked QTc prolongation
Study: 7732330
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg twice daily) + Ranitidine (150 mg twice daily)
Study: 8174947
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg twice daily)
Study: 2258379
Drug: Amitriptyline (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50-150 mg/day)
Study: 6991103
Drug: Chemoimmunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy with moderate doses of methotrexate and L-asparaginase added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide, along with Corynebacterium parvum or Pseudomonas vaccine.
Study: 28403798
Drug: Cobicistat-boosted darunavir
Normalized name: cobicistat / darunavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobicistat-boosted darunavir (800 mg) with 2 N(t)RTIs, once daily for 48 weeks
Study: 23669567
Drug: Intravesical oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical oxybutynin 10 mg
Study: 23669567
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin 5 mg
Study: 23669567
Drug: Intravesical oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical oxybutynin (7 doses of 10 mg)
Study: 19235072
Drug: Social-cognitive theories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-cognitive theories (e.g. Transtheoretical model, Theory of Planned Behaviour, Protection Motivation Theory, Social Cognitive Theory)
Study: 8944120
Drug: Iopamidol 370
Normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 370 mg l/l
Study: 8944120
Drug: Ioxaglate 350
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate 350 mg l/l
Study: 8944120
Drug: Iopamidol 300
Normalized name: iopamidol 300 mg iodine/mL (61 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 300 mg l/l
Study: 8944120
Drug: Ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate 320 mg l/l
Study: 1720488
Drug: Isradipine at
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine at 1.25‐2.5 mg twice daily
Study: 6749440
Drug: Sulconazole nitrate
Normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulconazole nitrate 1.0 percent cream
Study: 6749440
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate 2.0 percent cream
Study: 31850996
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluid regimen (S-group)
Study: 31850996
Drug: Restrictive intravenous
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive intravenous fluid regimen (R-group)
Study: 31141394
Drug: Sports drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports drink (Gatorade®); 805 ml fluid intake, 6.5 MJ energy intake, 187 g carbohydrate intake; p=0.002 for energy, p<0.001 for carbohydrate
Study: 31141394
Drug: Water; 751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water; 751 ml fluid intake, 5.7 MJ energy intake, 151 g carbohydrate intake
Study: 31141394
Drug: Sports drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports drink (Gatorade®); 1,047 ml acute fluid intake, 3,337 ml total fluid intake at end of trial days; p=0.004 for acute fluid intake, p<0.01 for total fluid intake
Study: 31141394
Drug: Low-alcohol beer
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-alcohol beer (Hahn Ultra®); 850 ml acute fluid intake, 2,982 ml total fluid intake at end of trial days
Study: 25867599
Drug: Enzyme-Modified Ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-Modified Ginseng Extract (EG) cream
Study: 19126049
Drug: Isotretinoin treatment
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin treatment group
Study: 19126049
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment group
Study: 16389910
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment allocation
Study: 12407487
Drug: Alcohol-based melaleuca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-based melaleuca oral solution, administered four times daily for 2-4 weeks
Study: 12407487
Drug: Alcohol-free melaleuca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-free melaleuca oral solution, administered four times daily for 2-4 weeks
Study: 8748337
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic cream, EMLA
Study: 8748337
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (Vaseline)
Study: 20662863
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants placed in fresh extraction sockets
Study: 20595193
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 3 g/day
Study: 20595193
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 1 g/day
Study: 17174460
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus petal 15 mg bid (morning and evening)
Study: 17174460
Drug: Fluoxetine 10
Normalized name: fluoxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10 mg bid (morning and evening)
Study: 12473257
Drug: Perhexiline treatment
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline treatment for 3 days
Study: 12473257
Drug: Perhexiline treatment
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline treatment
Study: 7699528
Drug: Prednisone 1
Normalized name: prednisone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1 mg/kg
Study: 7699528
Drug: Prednisone 2
Normalized name: prednisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2 mg/kg
Study: 18306372
Drug: Nontaxane-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontaxane-based therapies
Study: 10506041
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous 2.2 g dose of co-amoxiclav
Study: 8671156
Drug: Triptorelin (gonadotrophin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (gonadotrophin-releasing hormone agonist)
Study: 2006616
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Atenolol + Nifedipine)
Study: 6751338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 80 micrograms atropine methonitrate and 450 micrograms reproterol
Study: 31796028
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Care Package (OHCP) delivered to mothers of 1-6-year-old children
Study: 30033159
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg caffeine (placebo)
Study: 30033159
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment overall
Study: 30033159
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment and BMI
Study: 27236320
Drug: Voriconazole 50
Normalized name: voriconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 50 mg oral
Study: 27236320
Drug: Voriconazole 400
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 400 mg oral
Study: 27236320
Drug: Voriconazole 50
Normalized name: voriconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 50 mg intravenous
Study: 27236320
Drug: Voriconazole 400
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 400 mg intravenous
Study: 27236320
Drug: Voriconazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (both doses)
Study: 25007675
Drug: Local packing
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local packing of Nasopore combined with hemocoagulase injection (1 U of hemocoagulase dissolved in 0.5 ml saline)
Study: 25007675
Drug: Local packing
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local packing of Nasopore combined with saline injection (0.5 ml saline)
Study: 20926013
Drug: multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: multimodal analgesia protocol (oral celecoxib and tramadol before and after surgery; intra‐articular injection of morphine, ropivacaine, adrenaline, and betamethasone during surgery)
Study: 20926013
Drug: oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral and intra‐articular placebo
Study: 12435158
Drug: Chloroquine and
Normalized name: chloroquine and proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine and 5-day regimen of primaquine at 15 mg/day
Study: 11910651
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate 2.0 mg/dienogest 2.0 mg (Climodien)
Study: 11910651
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate 2.0 mg/dienogest 3.0 mg (E2Val 2/DNG 3)
Study: 11910651
Drug: Estradiol 2.0
Normalized name: Estradiol 2.083 microgram/hour prolonged-release vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2.0 mg/estriol 1.0 mg/norethisterone acetate 1.0 mg (Kliogest)
Study: 8478230
Drug: Strontium-89 (10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium-89 (10.8 mCi single injection)
Study: 3762845
Drug: Phenobarbital (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (combined loading and titration)
Study: 3762845
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than one agent (including diazepam)
Study: 23350933
Drug: Pay-for-performance program
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pay-for-performance program (P4P) providing A$40 and A$100 for diabetes and asthma treatment, and A$35 for cervical cancer screening.
Study: 17395029
Drug: Insulin-Glucose Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-Glucose Infusion
Study: 11149435
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with V(T) = 15 ml/kg ideal body weight on ZEEP
Study: 11149435
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with V(T) = 6 ml/kg ideal body weight on ZEEP
Study: 11149435
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with V(T) = 6 ml/kg ideal body weight on positive end‐expiratory pressure of 10 cm H2O
Study: 1493837
Drug: Penicillin (Phenoxymethylpenicillin)
Normalized name: Penicillin V
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin (Phenoxymethylpenicillin) 250 mg t.i.d. for adults and 125 mg t.i.d. for children
Study: 30537874
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy as an adjunct to intensive family preservation services (n = 14)
Study: 21905254
Drug: Pain group
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain group (n = 13) - resistance training during pain induced by injections of painful hypertonic saline
Study: 21905254
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 14) - resistance training during a nonpainful condition with injection of isotonic saline
Study: 17976337
Drug: Double-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose vitamin D
Study: 10496155
Drug: TETRAMUNE (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETRAMUNE (combination vaccine of HibTITER and DTP)
Study: 10496155
Drug: DTP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP and HibTITER administered concurrently (separate group)
Study: 7570885
Drug: Intrarectal Quinimax®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal Quinimax® (20 mg/kg)
Study: 7570885
Drug: Intramuscular Quinimax®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Quinimax® (12.5 mg/kg)
Study: 7570885
Drug: Intramuscular Quinimax®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Quinimax®
Study: 2668757
Drug: Single-dose ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ketoconazole (400 mg)
Study: 2668757
Drug: Single-dose ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ketoconazole (800 mg)
Study: 779006
Drug: Co-trimoxazole (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (320 mg trimethoprim and 1600 mg sulphamethoxazole daily for 10 days)
Study: 779006
Drug: Nitrofurantoin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (200 mg/day for 10 days)
Study: 31985266
Drug: ALTENS four‐times
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALTENS four‐times weekly for 6 weeks
Study: 31985266
Drug: ALTENS two‐times
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALTENS two‐times weekly for 12 weeks
Study: 30888217
Drug: Pycnogenol (PYC)
DrugBank: Maritime pine extract (DB15786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (PYC) 50 mg per day for 4 months
Study: 26883526
Drug: Pharmacist-assisted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and individualized telephone follow-up after discharge
Study: 28630194
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous fosfomycin disodium
Study: 28630194
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g intravenous fosfomycin disodium
Study: 28630194
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g oral fosfomycin tromethamine
Study: 23489710
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy administered by insulin pen
Study: 23489710
Drug: More positive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More positive expectations of insulin therapy
Study: 19180896
Drug: Calcipotriene 0.005%
Normalized name: CALCIPOTRIENE 0.005% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005% betamethasone dipropionate 0.064% ointment
Study: 18322602
Drug: Fufang Biejia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Biejia Ruangan tablet (FBRt)
Study: 18322602
Drug: He Luo
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: He Luo Shu Gan capsule (Control)
Study: 12136475
Drug: Immunodepressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunodepressive therapy
Study: 12136475
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse therapy with cyclophosphamide
Study: 12136475
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse therapy
Study: 7573298
Drug: Climara patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climara patch
Study: 27977819
Drug: Feather-edge preparation
Normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feather-edge preparation
Study: 23548118
Drug: Paeoniflorin (PAE)
Normalized name: Paeoniflorin
DrugBank: Peoniflorin (DB16288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paeoniflorin (PAE) + cervus and cucumis polypeptide injection (CCPI)
Study: 22462231
Drug: Amino-polypeptide as
Normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino-polypeptide as a basic treatment
Study: 19624787
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER (4 mg)
Study: 9046249
Drug: Vancomycin 20
Normalized name: vancomycin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 20 micrograms/mL and Gentamicin 8 micrograms/mL in the irrigating fluid
Study: 7959572
Drug: OK-432 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (administered pre-operatively via hepatic artery)
Study: 23595590
Drug: Topical zinc
Normalized name: bacitracin topical zinc compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical zinc oxide treatment
Study: 23595590
Drug: Parenteral zinc,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral zinc, copper, and selenium combined
Study: 21709199
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (1,000 mg of elemental calcium plus 400 IU of vitamin D3 daily)
Study: 19535421
Drug: Stearate-enriched plant
Normalized name: stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stearate-enriched plant sterol esters (3 g/d, 1 g three times per day with meals)
Study: 9431633
Drug: Specific exercise
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific exercise treatment program involving training of deep abdominal muscles and co-activation of lumbar multifidus for 10 weeks
Study: 9431633
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment as directed by treating practitioner
Study: 3388875
Drug: sucralfate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate (4 g/day)
Study: 3388875
Drug: ranitidinhydrochloride (336
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidinhydrochloride (336 mg/day)
Study: 3388875
Drug: ranitidinhydrochloride and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidinhydrochloride and pirenzepindihydrochloride (100 mg/day)